Krsnaa Diagnostics Limited has informed the Exchange regarding Outcome of Board Meeting held on May 12, 2025.
KRSNAA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 9.1 pts less than Nifty Microcap 250 and 7.0 pts less than its Healthcare Service Provider peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Krsnaa Diagnostics reported audited consolidated revenue from operations of INR 7,171.60 million for FY25, up about 15.7% from INR 6,196.33 million in FY24. Consolidated net profit for the year rose around 36.5% to INR 776.08 million from INR 568.37 million, while standalone net profit grew about 41.4% to INR 828.08 million. For Q4 FY25, standalone revenue grew to INR 1,746.53 million with a profit of INR 210.65 million. The auditor (MSKA & Associates) issued an unmodified opinion on both standalone and consolidated results. The Board recommended a final dividend of INR 2.75 per share (55% of face value), subject to shareholder approval. The auditor also drew attention to an income tax demand of INR 513.86 million across assessment years 2017-18 and 2020-21 to 2023-24, which the company is contesting in appeal; INR 39.27 million has been paid under protest and management expects no material impact.
Strong FY25 earnings growth, with profit rising over a third year-on-year, should be viewed positively by investors, while the recommended final dividend signals steady shareholder returns. However, the ongoing INR 513.86 million tax dispute remains a key overhang to watch, even though the company expects no material impact from the appeals.